Symbols

TVTX

Travere Therapeutics·NASDAQ

--(--)

TVTX fundamentals

TVTX Q4 2025 Earnings

Travere Therapeutics (TVTX) released its earnings on Feb 19, 2026: revenue was 126.61M (YoY +72.15%), missed estimates; EPS was 0.03 (YoY +104.11%), beat estimates.

Revenue / YoY

126.61M

+72.15%

EPS / YoY

0.03

+104.11%

Report date

Feb 19, 2026

TVTX Earnings Call Summary for Q4,2025

IgA Nephropathy Dominance: Q4 FILSPARI sales up 144% YoY, with record 908 new patient starts, solidifying leadership amid competition.
FSGS Regulatory Watch: PDUFA date extended to April 13, 2026, with FDA focused on proteinuria endpoint. FDA engagement reinforces confidence in FILSPARI's FSGS potential.
Pipeline Catalysts: Pegtibatinase Phase III resumes, targeting first disease-modifying therapy for homocystinuria. Q1 2026 demand trends support $1B+ IgA nephropathy peak sales.

Earnings

EPS

Revenue

Revenue & Expenses

TVTX has released its 2025 Q4 earnings report, with revenue of 129.69M, reflecting a YoY change of 73.41%, and net profit of 2.73M, showing a YoY change of 104.53%. The Sankey diagram below clearly presents TVTX's revenue sources and cost distribution.

Key Indicators

Travere Therapeutics (TVTX) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Travere Therapeutics (TVTX)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Travere Therapeutics (TVTX)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Travere Therapeutics (TVTX)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown